as of 01-22-2026 4:00pm EST
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 138.1M | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 64.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.57 - $26.50 | Next Earning Date: | 05-13-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
TTRX Breaking Stock News: Dive into TTRX Ticker-Specific Updates for Smart Investing
See how TTRX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "TTRX Turn Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.